Healiva is a patient-centric Biotech commercialising a portfolio of innovative, personalised and affordable life-enhancing precision medicine for chronic and acute wounds. The end-to-end approach has core enzyme technology and is paired with cell therapies or medical devices.
Products, services, technology
Epidex®/Healiva01 is an autologous cell graft promoting the closure of recalcitrant chronic ulcers. Healiva02, an allogeneic cell therapy targets venous leg ulcers. We are further developing 2 in-house products, the world`s first-in class spray based debrider and an autologous blood component patch.
In-licensing, Out-licensing, Business Development, Distribution.
Open to partner/ collaborate with hospitals, medical practitioners, insurance providers and patients associations.
The increasing prevalence of chronic wounds (including diabetes, advanced age, and obesity) is a detriment to quality of life. Our products addresses UN sustainable development goal (SDG) 3, ‘good health and well-being’, particularly target 3.4, ensuring healthy life and promoting well-being.
We are working towards comprehensive tailored solutions and a successful regimen can prevent osteomyelitis, hospitalization, amputation, and even death, allowing millions of patients to re-establish their normal work and life routines.
With a vision in mind to bring a paradigm shift in wound care, a core team of seasoned experts in wound care and cell therapy from the industry came together. New recruits joined Healiva to make a difference for patients and be part of an exciting journey from the beginning.
We heal life and make the world a better place.
By creating network experts, KOLs, and entrepreneurs to turn competition into opportunity. It is key to accept that you do not need to reinvent the wheel and you must learn from the industry to fast-track the innovation to market.
Our multifaceted customer base encompasses hospitals, medical practitioners, insurance providers, and patients.